الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 139 |  |  |
| | | from | 139 | | |
Abstract
Materials and methods: All patients included in this prospective study were subjected to: History: Date of birth ,Age of karyotyping, Age of onset of GH therapy ,Age of stoppage of GH therapy ,Duration of GH therapy ,Annual increament in height, Annual increament in weight, Initial GH dose ,Intelligence quotient, Bone age at the start and at the end Proved by X-RAY Examination: Standing height, Ht SDS, Weight, Wt SDS,BMI,BMI SDS, Maternal Ht, Paternal Ht, Mid parental height (MPH),Expected adult height ,US\LS ratio, Span ,waist\hip ratio ,Subischial Ht. Investigations: 1. GH Provocation test 2 .karyotyping 3.Abnormal thyroid function 4.Gonadal dysgenesis. by pelvic US. 5.Kidney abnormalities proved by abdominal US 6.Heart abnormalities proved by ECHO 7.Bone abnormalities proved by X-RAY. Results : GHRT led to significant improvements in height outcomes (Ht SDS) in TS patients with monosomy, isochromosome, and mosaic variants.There were observed differences in Height Standard Deviation Score (Ht SDS) after one year of GHRT among the monosomy, isochromosome, and mosaic variant groups, suggesting that karyotype variation plays a role in treatment response. Conclusions : In conclusion, the current study demonstrated that Growth Hormone Replacement Therapy (GHRT) has significant positive effects on height outcomes in Turner Syndrome (TS) patients with monosomy, isochromosome, and mosaic variants. Keywords : Growth Hormone, Turner Syndrome, karyotypes